
Reading Pipeline Data in Real Time: Hype, Promise, and Single-Arm Phase 2 Trials
How to tell a durable trend from hype, when a single-arm phase 2 is enough, and counseling patients on fast-moving pipelines in GU and head and neck cancer.
Desai: Let’s move on to where evidence-based practice is heading. How do we distinguish a trend that will actually stick from one that is more hype than substance? We all see studies that get hyped but then don’t prove clinically meaningful. How do you read pipeline data critically, especially when there are no confirmatory trials, and how do you discuss that with patients?
Kydd: One of the things we need to do is explain this to our patients — why a finding is not confirmatory, where the hype ends and the promise begins. Sometimes that is very hard. We don’t want to overpromise and leave patients feeling misled, but we also want to give them access to the most advanced treatments that are reasonable. Making sure patients understand the uncertainty — and are comfortable with it — is critical. We don’t want to give them something we don’t believe in, but we also sometimes need to switch gears.
Kydd: A good example is sacituzumab govitecan in bladder cancer. The original phase 2 was promising, but the phase 3 was ultimately negative and we had to pull back. There is still occasional off-label use, but it is not FDA approved in that setting. We need to be careful, and at the same time, as researchers, we can still pull pearls from a negative confirmatory trial that inform the next study and the next agent.
Desai: How do you talk about a hyped study without confirmatory data with your patients, Dr. Sun?
Sun: In head and neck cancer, sometimes it’s simply not realistic to do the confirmatory study. An important principle is that the weight we put on a single-arm phase 2 depends on what other therapies are available as standard. A recent example from our world: in head and neck squamous cell carcinoma, after immunotherapy and platinum-based chemotherapy, there’s a grab bag of mediocre single-agent chemotherapy options and cetuximab — no agreed-upon standard beyond those first two lines. We’ve been eagerly awaiting single-arm phase 2 data.
Sun: This past summer we saw data in the subsequent-line setting for amivantamab, an EGFR/MET bispecific antibody. It was a fairly large phase 2 study for our field — about 100 patients — with a response rate in the 40% to 45% range. That may not sound impressive to a breast cancer oncologist running a phase 3 with hundreds of patients, but for us this is game-changing data. Amivantamab is approved in other cancers, so current use in head and neck cancer is off-label, but it offers a response rate potentially double that of our other mediocre single-agent options and spares patients from more chemotherapy-related toxicity. Without other good options, I am using that phase 2 trial for my patients. I’m very realistic that I cannot definitively tell them it is better, but when you present them with what data we do have, most patients understand the uncertainty and want to proceed.
Desai: That’s an important point. In rare cancers you may never have a large randomized phase 3, so a well-done single-arm phase 2 with a strong signal is meaningful — especially when the standard of care isn’t robust. Dr. Sun, how do you counsel patients on an evolving treatment paradigm — comparing phase 2 agents with current standard of care?
Sun: Many of the agents I mentioned in later-line settings are also trying to move into the first-line setting for head and neck squamous cell carcinoma. As someone who runs clinical trials, I often use early encouraging data as motivation to try to enroll patients on confirmatory studies when they exist. Because the toxicity profiles of these newer agents often look favorable compared with immunotherapy plus chemotherapy, patients are frequently excited by the opportunity. It has to be a balanced discussion — we don’t yet know which is better, and we should recognize our own biases — but if a patient is randomized to the standard-of-care arm, that’s still a legitimate treatment.
Sun: Patients often ask when these drugs could become standard, and the hard reality for metastatic head and neck cancer is that even with data coming in the next few years, the median survival means many patients will not be here in time for those approvals. So the best thing we can do is encourage trial participation and build strong relationships with our community partners to offer these trials and therapeutics more widely across the country.
Related to this article







